Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4591681
Max Phase: Preclinical
Molecular Formula: C45H76N6O29
Molecular Weight: 1165.12
Molecule Type: Unknown
Associated Items:
ID: ALA4591681
Max Phase: Preclinical
Molecular Formula: C45H76N6O29
Molecular Weight: 1165.12
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@H]1[C@H](OCCCCCCN=[N+]=[N-])O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H]3O[C@H](CO)[C@@H](O)[C@@H](O[C@@H]4O[C@H](CO[C@]5(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O5)[C@H](O)[C@H](O)[C@H]4O)[C@H]3NC(C)=O)[C@H]2O)[C@@H]1O
Standard InChI: InChI=1S/C45H76N6O29/c1-16(56)48-25-19(59)10-45(44(69)70,80-38(25)28(61)20(60)11-52)72-15-24-29(62)33(66)34(67)42(76-24)78-37-27(50-18(3)58)41(73-21(12-53)30(37)63)79-39-31(64)22(13-54)74-43(35(39)68)77-36-23(14-55)75-40(26(32(36)65)49-17(2)57)71-9-7-5-4-6-8-47-51-46/h19-43,52-55,59-68H,4-15H2,1-3H3,(H,48,56)(H,49,57)(H,50,58)(H,69,70)/t19-,20+,21+,22+,23+,24+,25+,26+,27+,28+,29-,30+,31-,32+,33-,34+,35+,36+,37-,38+,39-,40+,41-,42-,43-,45+/m0/s1
Standard InChI Key: KCRARMFQBMRVCB-SVMDDNGNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1165.12 | Molecular Weight (Monoisotopic): 1164.4657 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Wu HR, Anwar MT, Fan CY, Low PY, Angata T, Lin CC.. (2019) Expedient assembly of Oligo-LacNAcs by a sugar nucleotide regeneration system: Finding the role of tandem LacNAc and sialic acid position towards siglec binding., 180 [PMID:31351394] [10.1016/j.ejmech.2019.07.046] |
Source(1):